# Richard Law

> Richard Law is the Chief Business Officer of HAYA Therapeutics, the Lausanne- and San Diego-based biotech decoding the 'dark genome' to build RNA-guided medicines that reprogram disease-driving cell states. A computational chemist turned dealmaker with a Oxford PhD in molecular biophysics and an Imperial MBA, he spent over a decade at Evotec, then steered Exscientia through its 2021 Nasdaq IPO, marquee pharma partnerships, and 2024 merger with Recursion before joining HAYA in March 2025 to drive its partnering strategy and growth.

- **Role:** Chief Business Officer at HAYA Therapeutics
- **Organizations:** HAYA Therapeutics, Exscientia, Evotec, Recursion Pharmaceuticals
- **Nationality:** British
- **Education:** B.Sc. in Biochemistry, University of Oxford, Ph.D. in Molecular Biophysics, University of Oxford, MBA, Imperial College London
- **Known for:** Led Exscientia's 2024 merger with Recursion Pharmaceuticals, Helped take Exscientia public on Nasdaq in 2021, Brokered partnerships for Exscientia with BMS, Sanofi, Merck Darmstadt, EQRX, and the Gates Foundation

## Career timeline

- **Early career** — Computational chemist in academia, biotech, and government labs in California
- **2008** — Joined Evotec as Global Head of Computational Chemistry
- **2013** — Became Senior Vice President of Business Development at Evotec, leading biotech investment strategy and drug discovery alliances
- **2020** — Joined Exscientia as Chief Business Officer
- **2021** — Helped lead Exscientia's Nasdaq IPO and the acquisition of Allcyte
- **2024** — Led Exscientia's merger with Recursion Pharmaceuticals
- **2025** — Appointed Chief Business Officer of HAYA Therapeutics (March)

## Achievements

- Led Exscientia's 2024 merger with Recursion Pharmaceuticals
- Helped take Exscientia public on Nasdaq in 2021
- Brokered partnerships for Exscientia with BMS, Sanofi, Merck Darmstadt, EQRX, and the Gates Foundation
- Oversaw Exscientia's acquisition of Allcyte
- Spent over a decade at Evotec, rising from Global Head of Computational Chemistry to SVP of Business Development
- Joined HAYA shortly before its $65M Series A round led by Sofinnova Partners and Earlybird Venture Capital

## Latest updates

- **2025-03** — Appointed Chief Business Officer of HAYA Therapeutics
- **2025-05** — HAYA closed a $65M Series A led by Sofinnova Partners and Earlybird Venture Capital, with participation from Eli Lilly
- **2026-05** — HAYA dosed the first cohort in its Phase 1 trial of HTX-001 for cardiac fibrosis

## Links

- Website: https://hayatx.com
- LinkedIn: https://www.linkedin.com/in/drrichjlaw
- Twitter/X: https://x.com/drrichjlaw

---

Profile page: https://yespress.io/richard-law
Published by YesPress — https://yespress.io
Last updated: 2026-06-08